Benjamin Kelmendi, Terence Ching
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Clinicians and researchers discuss integrating psilocybin-assisted therapy into serious illness care models, presenting preliminary findings from a pilot study in hospice care for patients with terminal illness.
Yvan Beaussant, Roxanne Sholevar, Lisa Summer, Robin McKenna
Psilocybin therapy tested for safety, feasibility, and efficacy in cancer patients with major depressive disorder, using group treatment in a cancer center setting. Clinical trial details: NCT04593563.
Betsy Jenkins
Roots To Thrive Non Profit pioneers legal psilocybin group therapy in North America, with published research, ongoing trials, and ties to a Canadian academic program. Emphasizing community in psychedelic mental
Todd Haspect, Akua Prieto Brown
Psilocybin trial for advanced cancer patients will compare effects of 25mg dose to 1mg placebo on anxiety, depression, and existential distress, using psychotherapy to assess efficacy and psychological mechanisms.
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Dr. Smith and Dr. Jones explore the latest research on psychedelic therapy and its potential impact on mental health during the PS2023 conference.
Stacy Fischer, Anthony “Tony” Bossis, Charles S Grob, Manish Agrawal, Shoshana Ungerleider
Study investigates oral psilocybin for cluster headaches. Subjects receive placebo, low or high dose psilocybin in 3 sessions, with headache diary monitoring. Second round may involve low or high dose
Emmanuelle Schindler
Psychedelics, historically linked to "free love", show potential for positive impact on sexual feelings. Recent research suggests psilocybin may enhance sexual functioning and satisfaction in healthy and depressed individuals.
Tommaso Barba
Executives of major psychedelic drug developers discuss building infrastructure for psychedelic therapy in healthcare, including education, clinics, EMR tools, and research to enhance outcomes.
Doug Drysdale
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.